TD Cowen analyst Yaron Werber raised the firm’s price target on BeiGene to $235 from $224 and keeps an Outperform rating on the shares. The firm said its exciting pipeline continues to progress with five NME’s entering the clinic in 2023 and ten poised to start Phase1 in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BGNE:
